Congenital fetal and neonatal visceral chylous effusions: Neonatal chylothorax and chylous ascites revisited. A multicenter retrospective study

Carlo Bellini, Z. Ergaz, M. Radicioni, I. Forner-Cordero, Marlys H Witte, G. Perotti, T. Figar, L. Tubaldi, P. Camerini, B. Bar-Oz, I. Yatsiv, I. Arad, F. Traverso, T. Bellini, F. Boccardo, C. Campisi, P. Dalmonte, N. Vercellino, S. Manikanti, E. Bonioli

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

This retrospective study was carried out at eight Neonatal Intensive Care Units (NICU) Centers worldwide on 33 newborns presenting at birth with pleural, pericardial, or abdominal chylous effusions. Diagnosis of chylous effusion is based on findings of fluid with a milk-like appearance, a concentration of triglycerides in pleural effusion >1.1 mmolll, and a total cell count >1,000 cells/ml with a predominance of >80% lymphocytes. Thirty- Three newborns met the inclusion criteria and were studied. Six subjects who presented at birth with fetal effusion were treated by in- utero pleuro-amniotic shunt. Five of these patients are alive at follow-up. At birth, pleural drainage was performed in 29/33 patients and abdominal drainage was carried out in 3/33. Total parenteral nutrition (TPN) was given to 32/33 patients; 19/23 patients were fed a medium-chain triglycerides (MCT). No adverse effects were observed. Eight patients were treated with Octreotide at dosages ranging from 1 to 7 mcg/kg/hour for 8 to 35 days. All patients showed decreased chylous production. Two patients were treated by pleurodesis. Twenty-two babies are alive after at least 6 months follow-up, 9/33 are deceased, and 2 were lost to follow-up. Clinical conditions of survivors are basically good except for lung involvement [chronic lung disease (CLD) or lung lymphangiectasia] and lymphedema. All patients were using a MCT diet at follow-up with good control of chylous effusion. Visceral chylous effusions of the fetus and neonate are rare disorders, and there currently is only partial agreement on decision-making strategies. We suggest the need for an international prospective trial in an effort to establish the efficacy and effectiveness of diagnostic and therapeutic options described in this article.

Original languageEnglish (US)
Pages (from-to)91-102
Number of pages12
JournalLymphology
Volume45
Issue number3
StatePublished - Sep 2012

Fingerprint

Chylous Ascites
Chylothorax
Multicenter Studies
Retrospective Studies
Triglycerides
Parturition
Newborn Infant
Drainage
Lymphangiectasis
Pleurodesis
Lung
Octreotide
Lymphedema
Total Parenteral Nutrition
Neonatal Intensive Care Units
Lost to Follow-Up
Pleural Effusion
Lung Diseases
Survivors
Decision Making

Keywords

  • Chylothorax
  • Chylous ascites
  • Congenital visceral effusion
  • Edema of the fetus
  • Fetal hydrops
  • Hydrothorax
  • Lymphatic abnormalities
  • MCT diet
  • Non-immune hydrops fetalis
  • Octreotide

ASJC Scopus subject areas

  • Immunology and Allergy
  • Hematology

Cite this

Bellini, C., Ergaz, Z., Radicioni, M., Forner-Cordero, I., Witte, M. H., Perotti, G., ... Bonioli, E. (2012). Congenital fetal and neonatal visceral chylous effusions: Neonatal chylothorax and chylous ascites revisited. A multicenter retrospective study. Lymphology, 45(3), 91-102.

Congenital fetal and neonatal visceral chylous effusions : Neonatal chylothorax and chylous ascites revisited. A multicenter retrospective study. / Bellini, Carlo; Ergaz, Z.; Radicioni, M.; Forner-Cordero, I.; Witte, Marlys H; Perotti, G.; Figar, T.; Tubaldi, L.; Camerini, P.; Bar-Oz, B.; Yatsiv, I.; Arad, I.; Traverso, F.; Bellini, T.; Boccardo, F.; Campisi, C.; Dalmonte, P.; Vercellino, N.; Manikanti, S.; Bonioli, E.

In: Lymphology, Vol. 45, No. 3, 09.2012, p. 91-102.

Research output: Contribution to journalArticle

Bellini, C, Ergaz, Z, Radicioni, M, Forner-Cordero, I, Witte, MH, Perotti, G, Figar, T, Tubaldi, L, Camerini, P, Bar-Oz, B, Yatsiv, I, Arad, I, Traverso, F, Bellini, T, Boccardo, F, Campisi, C, Dalmonte, P, Vercellino, N, Manikanti, S & Bonioli, E 2012, 'Congenital fetal and neonatal visceral chylous effusions: Neonatal chylothorax and chylous ascites revisited. A multicenter retrospective study', Lymphology, vol. 45, no. 3, pp. 91-102.
Bellini, Carlo ; Ergaz, Z. ; Radicioni, M. ; Forner-Cordero, I. ; Witte, Marlys H ; Perotti, G. ; Figar, T. ; Tubaldi, L. ; Camerini, P. ; Bar-Oz, B. ; Yatsiv, I. ; Arad, I. ; Traverso, F. ; Bellini, T. ; Boccardo, F. ; Campisi, C. ; Dalmonte, P. ; Vercellino, N. ; Manikanti, S. ; Bonioli, E. / Congenital fetal and neonatal visceral chylous effusions : Neonatal chylothorax and chylous ascites revisited. A multicenter retrospective study. In: Lymphology. 2012 ; Vol. 45, No. 3. pp. 91-102.
@article{ee4f00250b4446d097c499e993c40c6a,
title = "Congenital fetal and neonatal visceral chylous effusions: Neonatal chylothorax and chylous ascites revisited. A multicenter retrospective study",
abstract = "This retrospective study was carried out at eight Neonatal Intensive Care Units (NICU) Centers worldwide on 33 newborns presenting at birth with pleural, pericardial, or abdominal chylous effusions. Diagnosis of chylous effusion is based on findings of fluid with a milk-like appearance, a concentration of triglycerides in pleural effusion >1.1 mmolll, and a total cell count >1,000 cells/ml with a predominance of >80{\%} lymphocytes. Thirty- Three newborns met the inclusion criteria and were studied. Six subjects who presented at birth with fetal effusion were treated by in- utero pleuro-amniotic shunt. Five of these patients are alive at follow-up. At birth, pleural drainage was performed in 29/33 patients and abdominal drainage was carried out in 3/33. Total parenteral nutrition (TPN) was given to 32/33 patients; 19/23 patients were fed a medium-chain triglycerides (MCT). No adverse effects were observed. Eight patients were treated with Octreotide at dosages ranging from 1 to 7 mcg/kg/hour for 8 to 35 days. All patients showed decreased chylous production. Two patients were treated by pleurodesis. Twenty-two babies are alive after at least 6 months follow-up, 9/33 are deceased, and 2 were lost to follow-up. Clinical conditions of survivors are basically good except for lung involvement [chronic lung disease (CLD) or lung lymphangiectasia] and lymphedema. All patients were using a MCT diet at follow-up with good control of chylous effusion. Visceral chylous effusions of the fetus and neonate are rare disorders, and there currently is only partial agreement on decision-making strategies. We suggest the need for an international prospective trial in an effort to establish the efficacy and effectiveness of diagnostic and therapeutic options described in this article.",
keywords = "Chylothorax, Chylous ascites, Congenital visceral effusion, Edema of the fetus, Fetal hydrops, Hydrothorax, Lymphatic abnormalities, MCT diet, Non-immune hydrops fetalis, Octreotide",
author = "Carlo Bellini and Z. Ergaz and M. Radicioni and I. Forner-Cordero and Witte, {Marlys H} and G. Perotti and T. Figar and L. Tubaldi and P. Camerini and B. Bar-Oz and I. Yatsiv and I. Arad and F. Traverso and T. Bellini and F. Boccardo and C. Campisi and P. Dalmonte and N. Vercellino and S. Manikanti and E. Bonioli",
year = "2012",
month = "9",
language = "English (US)",
volume = "45",
pages = "91--102",
journal = "Lymphology",
issn = "0024-7766",
publisher = "International Society of Lymphology",
number = "3",

}

TY - JOUR

T1 - Congenital fetal and neonatal visceral chylous effusions

T2 - Neonatal chylothorax and chylous ascites revisited. A multicenter retrospective study

AU - Bellini, Carlo

AU - Ergaz, Z.

AU - Radicioni, M.

AU - Forner-Cordero, I.

AU - Witte, Marlys H

AU - Perotti, G.

AU - Figar, T.

AU - Tubaldi, L.

AU - Camerini, P.

AU - Bar-Oz, B.

AU - Yatsiv, I.

AU - Arad, I.

AU - Traverso, F.

AU - Bellini, T.

AU - Boccardo, F.

AU - Campisi, C.

AU - Dalmonte, P.

AU - Vercellino, N.

AU - Manikanti, S.

AU - Bonioli, E.

PY - 2012/9

Y1 - 2012/9

N2 - This retrospective study was carried out at eight Neonatal Intensive Care Units (NICU) Centers worldwide on 33 newborns presenting at birth with pleural, pericardial, or abdominal chylous effusions. Diagnosis of chylous effusion is based on findings of fluid with a milk-like appearance, a concentration of triglycerides in pleural effusion >1.1 mmolll, and a total cell count >1,000 cells/ml with a predominance of >80% lymphocytes. Thirty- Three newborns met the inclusion criteria and were studied. Six subjects who presented at birth with fetal effusion were treated by in- utero pleuro-amniotic shunt. Five of these patients are alive at follow-up. At birth, pleural drainage was performed in 29/33 patients and abdominal drainage was carried out in 3/33. Total parenteral nutrition (TPN) was given to 32/33 patients; 19/23 patients were fed a medium-chain triglycerides (MCT). No adverse effects were observed. Eight patients were treated with Octreotide at dosages ranging from 1 to 7 mcg/kg/hour for 8 to 35 days. All patients showed decreased chylous production. Two patients were treated by pleurodesis. Twenty-two babies are alive after at least 6 months follow-up, 9/33 are deceased, and 2 were lost to follow-up. Clinical conditions of survivors are basically good except for lung involvement [chronic lung disease (CLD) or lung lymphangiectasia] and lymphedema. All patients were using a MCT diet at follow-up with good control of chylous effusion. Visceral chylous effusions of the fetus and neonate are rare disorders, and there currently is only partial agreement on decision-making strategies. We suggest the need for an international prospective trial in an effort to establish the efficacy and effectiveness of diagnostic and therapeutic options described in this article.

AB - This retrospective study was carried out at eight Neonatal Intensive Care Units (NICU) Centers worldwide on 33 newborns presenting at birth with pleural, pericardial, or abdominal chylous effusions. Diagnosis of chylous effusion is based on findings of fluid with a milk-like appearance, a concentration of triglycerides in pleural effusion >1.1 mmolll, and a total cell count >1,000 cells/ml with a predominance of >80% lymphocytes. Thirty- Three newborns met the inclusion criteria and were studied. Six subjects who presented at birth with fetal effusion were treated by in- utero pleuro-amniotic shunt. Five of these patients are alive at follow-up. At birth, pleural drainage was performed in 29/33 patients and abdominal drainage was carried out in 3/33. Total parenteral nutrition (TPN) was given to 32/33 patients; 19/23 patients were fed a medium-chain triglycerides (MCT). No adverse effects were observed. Eight patients were treated with Octreotide at dosages ranging from 1 to 7 mcg/kg/hour for 8 to 35 days. All patients showed decreased chylous production. Two patients were treated by pleurodesis. Twenty-two babies are alive after at least 6 months follow-up, 9/33 are deceased, and 2 were lost to follow-up. Clinical conditions of survivors are basically good except for lung involvement [chronic lung disease (CLD) or lung lymphangiectasia] and lymphedema. All patients were using a MCT diet at follow-up with good control of chylous effusion. Visceral chylous effusions of the fetus and neonate are rare disorders, and there currently is only partial agreement on decision-making strategies. We suggest the need for an international prospective trial in an effort to establish the efficacy and effectiveness of diagnostic and therapeutic options described in this article.

KW - Chylothorax

KW - Chylous ascites

KW - Congenital visceral effusion

KW - Edema of the fetus

KW - Fetal hydrops

KW - Hydrothorax

KW - Lymphatic abnormalities

KW - MCT diet

KW - Non-immune hydrops fetalis

KW - Octreotide

UR - http://www.scopus.com/inward/record.url?scp=84876089621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876089621&partnerID=8YFLogxK

M3 - Article

C2 - 23342929

AN - SCOPUS:84876089621

VL - 45

SP - 91

EP - 102

JO - Lymphology

JF - Lymphology

SN - 0024-7766

IS - 3

ER -